

**REMARKS**

Claims 66 and 67 are cancelled by this amendment. Claims 65 and 72 have been amended. Claim 65 has been amended to delete the recitation "or a variant, mutant or fragment thereof having the same function". Claim 72 has been amended to correct grammatical errors. New claim 74 has been added. Support for new claim 72 can be found throughout the specification, *inter alia*, page 2, last paragraph, spanning page 3. Claims 65, 68, 69, 72 and 74 are presently under consideration.

No new matter has been added.

**Rejections under 35 U.S.C. §112, First Paragraph**

Claims 65-69 are rejected under 35 U.S.C. §112, first paragraph for lack of enablement. The Examiner contends that the specification, while being enabling for the recited methods wherein the FPRL-1 receptor comprises SEQ ID NO:2, does not reasonably provide enablement for the methods reciting variants, mutants or fragments of SEQ ID NO:2.

As a preliminary matter, Applicants point out that claims 66 and 67 have been cancelled thereby making this rejection moot with respect to these claims.

With respect to this Section 112 rejection of claims 65-69, Applicants disagree; however, in order to advance prosecution of certain embodiments of the invention, claim 65 (and claims 68, 69, 72, and 74 dependent thereon) has been amended to delete the recitation "or a variant, mutant or fragment thereof having the same function".

In view of the foregoing, Applicants respectfully submit that all of the pending claims are enabled under Section 112 and requests withdrawal of this rejection.

**Claim Objections**

Claim 72 is objected to as being dependent upon a rejected claim base.

Applicants submit that in light of the amendments to claim 65, upon which claim 72 depends, this objection has been obviated and must be withdrawn.

**CONCLUSION**

- Applicants respectfully request the entry of the foregoing amendments and remarks into the file of the above-captioned application. Applicants believe that each ground for rejection or objection has been successfully overcome and that the application is in condition for allowance. Withdrawal of the Examiner's rejections and allowance of the application is earnestly requested. If any issues remain in connection herewith, the Examiner is respectfully invited to telephone the undersigned to discuss the same.

Respectfully submitted,




Susan K. Pocchiari  
Attorney for Applicant(s)  
Reg. No. 45,016

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT 06877  
Tel.: (203) 798-5648

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on February 26, 2004



By: Susan K. Pocchiari  
Reg. No. 45,016